Antitumor host immunity enhanced by near‐infrared photoimmunotherapy

Hiroshi Fukushima,Aki Furusawa,Ryuhei Okada,Yasuhisa Fujii,Peter L. Choyke,Hisataka Kobayashi

DOI: https://doi.org/10.1111/cas.16427

IF: 5.7

2024-12-14

Cancer Science

Abstract:Near‐infrared photoimmunotherapy (NIR‐PIT) is a novel antitumor therapy that selectively kills cancer cells by NIR light‐triggered transformation of IRDye700DX within Ab–photoabsorber conjugates (APCs). NIR‐PIT effectively induces immunogenic cell death, immune cell migration between the tumor and tumor‐draining lymph node, and expansion of multiclonal tumor‐infiltrating CD8+ T cells. Crucially, cytotoxic effects of NIR‐PIT exert only cancer cells, sparing immune cells such as antigen‐presenting cells and T cells, key players in boosting antitumor host immunity. By modifying the Ab used in APC synthesis, NIR‐PIT can target and deplete noncancerous immunosuppressive cells including regulatory T cells, myeloid‐derived suppressor cells, and cancer‐associated fibroblasts, in the tumor microenvironment. Immunosuppressive cell‐targeted NIR‐PIT strongly potentiate antitumor host immunity, including the induction of abscopal effects and the development of immune memory. Furthermore, antitumor immune responses and therapeutic efficacy are synergistically enhanced when combining NIR‐PIT with other immune‐activating treatments, such as interleukin‐15 and immune checkpoint inhibitors. This evidence identifies NIR‐PIT as a valuable tool in the evolving landscape of cancer immunotherapy. This review presents the role of NIR‐PIT in activating antitumor host immunity. Near‐infrared photoimmunotherapy (NIR‐PIT) is a novel antitumor therapy that selectively kills cancer cells by NIR light‐triggered photochemical reaction of IRDye700DX within Ab–photoabsorber conjugates (APCs). NIR‐PIT induces immunogenic cell death, causing immune cell migration between the tumor and tumor‐draining lymph nodes, and expanding multiclonal tumor‐infiltrating CD8+ T cells. Crucially, the cytotoxic effects of NIR‐PIT are limited to cancer cells, sparing immune cells such as antigen‐presenting cells and T cells, which are key players in boosting antitumor host immunity. By modifying the Ab used in APC synthesis, NIR‐PIT can be repurposed to target and deplete noncancerous immunosuppressive cells including regulatory T cells, myeloid‐derived suppressor cells, and cancer‐associated fibroblasts in the tumor microenvironment. Immunosuppressive cell targeted NIR‐PIT strongly potentiates antitumor host immunity, including the induction of abscopal effects and the development of immune memory. Furthermore, antitumor immune responses and therapeutic efficacy are synergistically enhanced when NIR‐PIT is combined with other immune‐activating treatments, such as interleukin‐15 and immune checkpoint inhibitors. These new findings make NIR‐PIT a valuable tool in the evolving landscape of cancer immunotherapy. This review explains the role of NIR‐PIT in activating antitumor host immunity.

oncology